Symbols

NPCE

NeuroPace·NASDAQ

--(--)

Signals Analysis

Bullish signal 6

Bearish signal 0

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

MACD Golden Cross

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NPCE

Neuropace, Inc.

A commercial stage medical device company focused on solutions for epilepsy

Industry

Healthcare Equipment and Supplies

Established Date

11/19/1997

Listing Date

04/22/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

209

Fiscal Year Ends

12-31

Website

www.neuropace.com

Security Type

Common stock

Office address

455 N. Bernardo Avenue, Mountain View, CA 94043

Business

Introduction

NeuroPace, Inc., was incorporated in Delaware on November 19, 1997. The company is a medical device company focused on the treatment of epilepsy, and its RNS system is a brain reactive neuromodulation platform capable of providing personalized real-time treatment at the source of epileptic seizures. This is the first and only commercialized system of its kind designed to reduce or eliminate disruptive seizures in patients with refractory epilepsy.

Company Financials

EPS

NPCE has released its 2025 Q4 earnings. EPS was reported at -0.08, versus the expected -0.18, beating expectations. The chart below visualizes how NPCE has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

NPCE has released its 2025 Q4 earnings report, with revenue of 26.59M, reflecting a YoY change of 23.86%, and net profit of -2.73M, showing a YoY change of 48.02%. The Sankey diagram below clearly presents NPCE's revenue sources and cost distribution.